Fda grants priority review for supplemental biologics license application (sbla) of padcev® (enfortumab vedotin-ejfv) with keytruda® (pembrolizumab) for first-line treatment of advanced bladder cancer

Bothell, wash. & tokyo--(business wire)--seagen inc. (nasdaq: sgen) and astellas pharma inc. (tse:4503) today announced that on november 30, 2023 the u.s. food and drug administration (fda) accepted for priority review a supplemental biologics license application (sbla) for padcev® (enfortumab vedotin-ejfv) with keytruda® (pembrolizumab) as a combination therapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/muc), a form of bladder cancer that has.
SGEN Ratings Summary
SGEN Quant Ranking